A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Paraneoplastic, Autoantibody Evaluation, Serum
MessageFor Specimen Integrity during Extreme Weather see the “Lockbox Usage in Extreme Weather” document at the top of this page.
Test Code
PAVAL
Alias/See Also
Paraneoplastic Antibodies,
Paraneoplastic Neurological Autoimmunity
Paraneoplastic Neurological Autoimmunity
CPT Codes
83519; 86255x9, 86596
Includes
PAINT Interpretive Comments
AMPHS Amphiphysin Ab, S
AGN1S Anti-Glial Nuclear Ab, Type 1
ANN1S Anti-Neuronal Nuclear Ab, Type 1
ANN2S Anti-Neuronal Nuclear Ab, Type 2
ANN3S Anti-Neuronal Nuclear Ab, Type 3
CRMS CRMP-5-IgG, S
VGKC Neuronal (V-G) K+ Channel Ab, S
CCPQ P/Q-Type Calcium Channel Ab
PCABP Purkinje Cell Cytoplasmic Ab Type 1
PCAB2 Purkinje Cell Cytoplasmic Ab Type 2
PCATR Purkinje Cell Cytoplasmic Ab Type Tr
AMPHS Amphiphysin Ab, S
AGN1S Anti-Glial Nuclear Ab, Type 1
ANN1S Anti-Neuronal Nuclear Ab, Type 1
ANN2S Anti-Neuronal Nuclear Ab, Type 2
ANN3S Anti-Neuronal Nuclear Ab, Type 3
CRMS CRMP-5-IgG, S
VGKC Neuronal (V-G) K+ Channel Ab, S
CCPQ P/Q-Type Calcium Channel Ab
PCABP Purkinje Cell Cytoplasmic Ab Type 1
PCAB2 Purkinje Cell Cytoplasmic Ab Type 2
PCATR Purkinje Cell Cytoplasmic Ab Type Tr
Preferred Specimen
4 mL serum Red Top Tube
Patient Preparation
Patient Preparation:
1. For optimal antibody detection, specimen collection is recommended prior to initiation of immunosuppressant medication or intravenous immunoglobulin (IVIg) treatment.
2. This test should not be requested in patients who have recently received radioisotopes, therapeutically or diagnostically, because of potential assay interference. The specific waiting period before specimen collection will depend on the isotope administered, the dose given, and the clearance rate in the individual patient. Specimens will be screened for radioactivity prior to analysis. Radioactive specimens received in the laboratory will be held 1 week and assayed if sufficiently decayed, or canceled if radioactivity remains.
3. Patient should have no general anesthetic or muscle-relaxant drugs in the previous 24 hours.
Minimum Volume
2 mL serum
Other Acceptable Specimens
4 mL serum from SST
Instructions
Centrifuge Red Top tube, Aliquot Serum into a Pour off tube
Transport Container
Pour off tube
Transport Temperature
Refrigerated
Specimen Stability
Room Temperature: 72 hours
Refrigerated: 28 days
Frozen: 28 days
Refrigerated: 28 days
Frozen: 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis, gross lipemia, gross icterus
Methodology
Indirect Immunofluorescence Assay, Radioimmunoassay, Cell-Binding Assay
Setup Schedule
Daily
Report Available
10 - 17 days
Limitations
Negative results do not exclude cancer. Intravenous immunoglobulin (IVIg) treatment prior to the serum collection may cause a false-positive result. This evaluation does not include Ma2 autoantibody (alias MaTa). Ma2 autoantibody has been described in patients with brainstem and limbic encephalitis in the context of testicular germ cell neoplasms. Scrotal ultrasound is advisable in men who present with unexplained subacute encephalitis. N-methyl-D-asparate receptor antibodies have been reported in women with paraneoplastic encephalitis related to ovarian teratoma.
Clinical Significance
Serological evaluation of patients who present with a subacute neurological disorder of undetermined etiology, especially those with known risk factors for cancer
Directing a focused search for cancer Investigating neurological symptoms that appear in the course of, or after, cancer therapy, and are not explainable by metastasis
Differentiating autoimmune neuropathies from neurotoxic effects of chemotherapy
Monitoring the immune response of seropositive patients in the course of cancer therapy
Detecting early evidence of cancer recurrence in previously seropositive patients
Directing a focused search for cancer Investigating neurological symptoms that appear in the course of, or after, cancer therapy, and are not explainable by metastasis
Differentiating autoimmune neuropathies from neurotoxic effects of chemotherapy
Monitoring the immune response of seropositive patients in the course of cancer therapy
Detecting early evidence of cancer recurrence in previously seropositive patients
Performing Laboratory
Mayo Clinic Laboratories
200 First Street SW
Rochester, MN 55905
Last Updated: August 8, 2023